Borregaard ASA
Norway · NO0010657505 · reports in NOK · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue +1.3% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 11% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 61% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in NOK.
NOK 7.7B
revenue
17%
operating margin
NOK 620M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | NOK 6.9B | NOK 7.1B | NOK 7.6B | NOK 7.7B |
| Operating profit | NOK 1.2B | NOK 1.3B | NOK 1.3B | NOK 1.3B |
| Net profit to shareholders | NOK 892M | NOK 870M | NOK 823M | NOK 620M |
| Earnings per share | NOK 8.95 | NOK 8.73 | NOK 8.25 | NOK 6.22 |
| Dividend per share | NOK 2.75 | n/a | NOK 4.25 | n/a |
| Cash from operations | NOK 735M | NOK 1.6B | NOK 1.1B | NOK 1.4B |
| Cash | NOK 234M | NOK 469M | NOK 82M | NOK 91M |
| Total assets | NOK 8.1B | NOK 9.1B | NOK 9.6B | NOK 9.7B |
| Equity | NOK 4.4B | NOK 4.9B | NOK 5.1B | NOK 5.9B |
What they do
In the company's own words, from the annual report.
Borregaard develops, produces and markets specialised biochemicals and biomaterials to a wide range of customers operating in global niche markets.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.